Lineage Cell Therapeutics Q1 2025 net loss narrows to $4.1M; cash runway into Q1 2027

Lineage Cell Therapeutics, Inc.

2025-Q1 EPS reported -$0.02 revenue$1,502,000

Net loss attributable of $4.1M ($0.02/shr) vs $6.5M ($0.04/shr) in Q1 2024; revenue $1.5M (flat YoY).
Cash and marketable securities of $47.9M as of Mar 31, 2025 expected to fund operations into Q1 2027.
OpRegen 36-month data to be presented June 21 at CTS 2025; OPC1 DOSED study initiated Feb 2025 for spinal cord injury.
3rd Annual SCI Investor Symposium announced with Christopher & Dana Reeve Foundation, virtual starting June 27, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.